Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

详细信息	查看全文 | 推荐本文 |

• 作者：Steven M. Trifilio^a ; ^c ; ^{strifili@nmh.org} ; Alfred W. Rademaker^b ; Diane Newman^a ; Katherine Coyle^a ; Katrin Carlson-Leuer^c ; ^d ; Jayesh Mehta^c ; Jessica Altman^c ; Olga Frankfurt^c ; Martin S. Tallman^e
• 关键词：Mitoxantrone ; Etoposide ; Cytarabine ; Acute myeloid leukemia
• 刊名：Leukemia Research
• 出版年：2012
• 期刊代码：186_01452126
• 类别：med
• 出版时间：April, 2012
• 卷：36
• 期：4
• 页码：394-396
• 文件大小：180 K

摘要

Mitoxantrone and etoposide (ME) salvage regimens have been successfully used for the treatment of primary induction failure or relapsed acute myeloid leukemia (AML). Whether the addition of intermediate dose cytarabine to ME increases complete remissions is unknown. To date, these regimens have not been directly compared. Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics. Differences in CR between ME and MEC subsets were analyzed to determine the effect of cytarabine to ME.